Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Novaremed Completes Enrollment in Phase 2b Chronic Pain Drug Trial
Details : NRD.E1 (or NRD135S.E1), an orally active small molecule with a novel mechanism of action, is being developed to treat chronic pain associated with diabetic peripheral neuropathy.
Product Name : NRD.E1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2025
Details : NeuroFront receives an exclusive option for an exclusive license to develop, commercialize and manufacture NRD.E1, Novaremed’s first-in-class, non-opioid investigational drug for the treatment of chronic neuropathic pain in Greater China and Singapore.
Product Name : NRD.E1
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 21, 2022
Details : In summary, data from these 4 studies now published demonstrate the potential of NRD.E1 (NRD135S.E1) as an innovative non-opioid treatment option for patients with painful diabetic peripheral neuropathy (PDPN).
Product Name : NRD.E1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 23, 2022
Details : The primary efficacy endpoint aims to demonstrate superiority of NRD.E1 compared to placebo in relieving PDPN. The secondary objectives of the study are to evaluate the pharmacokinetics, safety, and tolerability of NRD.E1, and assess several additional e...
Product Name : NRD.E1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 21, 2021
Novaremed Secures US $50 Million Capital Commitment from Global Emerging Markets
Details : The proceeds from this financing will be used to progress the clinical development of Novaremed’s lead product, NRD135S.E1, an investigational non-opioid small molecule drug for the treatment of painful diabetic peripheral neuropathy (PDPN).
Product Name : NRD.E1
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 28, 2021
Details : In a Phase 2a Proof of Concept study, NRD135S.E1 showed clinically relevant reduction in patient-reported pain and an excellent safety and tolerability profile. Novaremed Ltd is currently preparing to conduct a Phase 2b study in PDPN patients in USA.
Product Name : NRD.E1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 18, 2020
Details : The Phase 2 study, designed as a randomized, double-blind, placebo-controlled study, will enroll patients with neuropathic pain caused by Diabetes Mellitus. Eligible patients will be randomized to receive oral doses of either NRD135S.E1 or placebo once d...
Product Name : NRD.E1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 25, 2020